Abstract
Precision oncology has made progress in recent years and is currently at the heart of revolutionizing cancer research. In May 2019, two comprehensive genomic profiling (CGP) tests were approved with reimbursement in Japan: FoundationOne CDx Cancer Genomic Profile and OncoGuide NCC Oncopanel System, which are fully covered by the national health insurance system. It has been reported that only 3.7% of patients received sequencing-directed therapy (Sunami et al., Int J Clin Oncol, 2021). The Ministry of Health, Labor and Welfare reported that in 2021, only 8.1% of patients received sequencing-directed therapy after CGP tests.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
